MBX - CIK 0001776111
The table below shows MBX Biosciences, Inc.'s cash flow statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Operating cash flow | -$79.95M | -$54.68M | -$31.98M |
| Capital expenditure | $1.93M | $874.00K | $129.00K |
| Investing cash flow | -$83.70M | -$160.59M | -$30.93M |
| Dividends paid | - | - | - |
| Stock buybacks | - | - | - |
| Financing cash flow | $189.59M | $234.10M | $69.22M |
MBX Biosciences, Inc. reported operating cash flow of -$79.95M for fiscal year 2025. That is down 46.2% from -$54.68M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.